SCHEMBL6921685

SCHEMBL6921685

O=c1c2ccc(-c3ccccn3)cc2nc2n1CC(CO)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP3A4 P08684 1/20 0.38
NSD2 O96028 1/20 0.38
METAP2 P50579 2/20 0.36
DHODH Q02127 1/20 0.36
PRMT5 O14744 2/20 0.36
WDR77 Q9BQA1 1/20 0.36
HIF1A Q16665 1/20 0.35
KDM2B Q8NHM5 2/20 0.35
TGFBR1 P36897 1/20 0.34
RET P07949 2/20 0.34
ABL1 P00519 1/20 0.34
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNB4 P30926 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA7 P36544 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921658 0.90 NPC1 (0.41) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6922310 0.90 NPC1 (0.41) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL14238847 0.90 CYP3A4 (0.38) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL12059330 0.87 CYP3A4 (0.39) NPC1RAB9ATDP1CYP3A4METAP2
SCHEMBL6920430 0.84 CYP3A4 (0.40) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL14239807 0.82 NPC1 (0.38) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL14240294 0.81 USP30 (0.37) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL14238851 0.81 METAP2 (0.39) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL14239317 0.80 NPC1 (0.36) NPC1RAB9ATDP1CYP3A4NSD2
SCHEMBL6920498 0.80 CYP3A4 (0.40) NPC1RAB9ATDP1CYP3A4NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 NPC1 811/4885RAB9A 1387/4885TDP1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.